YTHDF2 and gastroesophageal junction adenocarcinoma: HER2 overexpression is detected in ≈7.3–20.2% of patients with advanced gastric/gastroesophageal junction adenocarcinoma, which led to the emergence of trastuzumab, an anti‐HER2 antibody, as the established first‐line treatment for patients with advanced metastatic HER2‐positive GC.[29] Considering a previous study indicating that ERK1/2‐mediated phosphorylation enhances YTHDF2 stability,[30] along with the high sequence similarity between YTHDF1 and YTHDF2, it is probable that HER2 activation may enhance YTHDF1 protein stability through a phosphorylation‐dependent mechanism.